These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

491 related articles for article (PubMed ID: 31403867)

  • 21. Phase 1b study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced melanoma (KEYNOTE-041).
    Yamazaki N; Takenouchi T; Fujimoto M; Ihn H; Uchi H; Inozume T; Kiyohara Y; Uhara H; Nakagawa K; Furukawa H; Wada H; Noguchi K; Shimamoto T; Yokota K
    Cancer Chemother Pharmacol; 2017 Apr; 79(4):651-660. PubMed ID: 28283736
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Open-label, phase II study of talimogene laherparepvec plus pembrolizumab for the treatment of advanced melanoma that progressed on prior anti-PD-1 therapy: MASTERKEY-115.
    Robert C; Gastman B; Gogas H; Rutkowski P; Long GV; Chaney MF; Joshi H; Lin YL; Snyder W; Chesney JA
    Eur J Cancer; 2024 Aug; 207():114120. PubMed ID: 38870745
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial.
    Naing A; Wong DJ; Infante JR; Korn WM; Aljumaily R; Papadopoulos KP; Autio KA; Pant S; Bauer TM; Drakaki A; Daver NG; Hung A; Ratti N; McCauley S; Van Vlasselaer P; Verma R; Ferry D; Oft M; Diab A; Garon EB; Tannir NM
    Lancet Oncol; 2019 Nov; 20(11):1544-1555. PubMed ID: 31563517
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study.
    Yan XQ; Ye MJ; Zou Q; Chen P; He ZS; Wu B; He DL; He CH; Xue XY; Ji ZG; Chen H; Zhang S; Liu YP; Zhang XD; Fu C; Xu DF; Qiu MX; Lv JJ; Huang J; Ren XB; Cheng Y; Qin WJ; Zhang X; Zhou FJ; Ma LL; Guo JM; Ding DG; Wei SZ; He Y; Guo HQ; Shi BK; Liu L; Liu F; Hu ZQ; Jin XM; Yang L; Zhu SX; Liu JH; Huang YH; Xu T; Liu B; Sun T; Wang ZJ; Jiang HW; Yu DX; Zhou AP; Jiang J; Luan GD; Jin CL; Xu J; Hu JX; Huang YR; Guo J; Zhai W; Sheng XN
    Ann Oncol; 2024 Feb; 35(2):190-199. PubMed ID: 37872020
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial.
    Powles T; Plimack ER; Soulières D; Waddell T; Stus V; Gafanov R; Nosov D; Pouliot F; Melichar B; Vynnychenko I; Azevedo SJ; Borchiellini D; McDermott RS; Bedke J; Tamada S; Yin L; Chen M; Molife LR; Atkins MB; Rini BI
    Lancet Oncol; 2020 Dec; 21(12):1563-1573. PubMed ID: 33284113
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial.
    Liu J; Liu Q; Li Y; Li Q; Su F; Yao H; Su S; Wang Q; Jin L; Wang Y; Lau WY; Jiang Z; Song E
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32448804
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors.
    Frentzas S; Austria Mislang AR; Lemech C; Nagrial A; Underhill C; Wang W; Wang ZM; Li B; Xia Y; Coward JIG
    J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38642937
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial.
    Long GV; Atkinson V; Cebon JS; Jameson MB; Fitzharris BM; McNeil CM; Hill AG; Ribas A; Atkins MB; Thompson JA; Hwu WJ; Hodi FS; Menzies AM; Guminski AD; Kefford R; Kong BY; Tamjid B; Srivastava A; Lomax AJ; Islam M; Shu X; Ebbinghaus S; Ibrahim N; Carlino MS
    Lancet Oncol; 2017 Sep; 18(9):1202-1210. PubMed ID: 28729151
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Phase I Study of the Anti-CC Chemokine Receptor 4 Antibody, Mogamulizumab, in Combination with Nivolumab in Patients with Advanced or Metastatic Solid Tumors.
    Doi T; Muro K; Ishii H; Kato T; Tsushima T; Takenoyama M; Oizumi S; Gemmoto K; Suna H; Enokitani K; Kawakami T; Nishikawa H; Yamamoto N
    Clin Cancer Res; 2019 Nov; 25(22):6614-6622. PubMed ID: 31455681
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety, Efficacy, and Biomarker Analysis of Toripalimab in Previously Treated Advanced Melanoma: Results of the POLARIS-01 Multicenter Phase II Trial.
    Tang B; Chi Z; Chen Y; Liu X; Wu D; Chen J; Song X; Wang W; Dong L; Song H; Wu H; Feng H; Yao S; Qin S; Zhang X; Guo J
    Clin Cancer Res; 2020 Aug; 26(16):4250-4259. PubMed ID: 32321714
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial.
    Wilky BA; Trucco MM; Subhawong TK; Florou V; Park W; Kwon D; Wieder ED; Kolonias D; Rosenberg AE; Kerr DA; Sfakianaki E; Foley M; Merchan JR; Komanduri KV; Trent JC
    Lancet Oncol; 2019 Jun; 20(6):837-848. PubMed ID: 31078463
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of surufatinib plus toripalimab, a chemotherapy-free regimen, in patients with advanced gastric/gastroesophageal junction adenocarcinoma, esophageal squamous cell carcinoma, or biliary tract cancer.
    Zhang P; Chen Z; Shi S; Li Z; Ye F; Song L; Zhang Y; Yin F; Zhang X; Xu J; Cheng Y; Su W; Shi M; Fan S; Tan P; Zhong C; Lu M; Shen L
    Cancer Immunol Immunother; 2024 May; 73(7):119. PubMed ID: 38713205
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Toripalimab for the treatment of melanoma.
    Tang B; Chi Z; Guo J
    Expert Opin Biol Ther; 2020 Aug; 20(8):863-869. PubMed ID: 32406293
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A first-in-human, open-label, dose-escalation and dose-expansion phase I study to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics, and antitumor activity of QL1604, a humanized anti-PD-1 mAb, in patients with advanced or metastatic solid tumors.
    Huang Z; Xu Y; Hong W; Gong L; Chen K; Qin J; Xie F; Wang F; Tian X; Meng X; Feng W; Li L; Zhang B; Kang X; Fan Y
    Front Immunol; 2023; 14():1258573. PubMed ID: 37936687
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of interferon-alpha 1b combined with PD-1 monoclonal antibody in patients with unresectable stage IV melanoma: a retrospective study.
    Zhu G; Shi Q; Zhao B; Liu Y; Feng T; Li C; Gao T
    J Cancer Res Clin Oncol; 2023 Aug; 149(9):6263-6269. PubMed ID: 36717393
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials.
    Fang W; Yang Y; Ma Y; Hong S; Lin L; He X; Xiong J; Li P; Zhao H; Huang Y; Zhang Y; Chen L; Zhou N; Zhao Y; Hou X; Yang Q; Zhang L
    Lancet Oncol; 2018 Oct; 19(10):1338-1350. PubMed ID: 30213452
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase II study evaluating the efficacy, safety, and pharmacodynamic correlative study of dual antiangiogenic inhibition using bevacizumab in combination with sorafenib in patients with advanced malignant melanoma.
    Mahalingam D; Malik L; Beeram M; Rodon J; Sankhala K; Mita A; Benjamin D; Ketchum N; Michalek J; Tolcher A; Wright J; Sarantopoulos J
    Cancer Chemother Pharmacol; 2014 Jul; 74(1):77-84. PubMed ID: 24817603
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of the efficacy of immunotherapy for non-resectable mucosal melanoma.
    Moya-Plana A; Herrera Gómez RG; Rossoni C; Dercle L; Ammari S; Girault I; Roy S; Scoazec JY; Vagner S; Janot F; Eggermont AMM; Robert C
    Cancer Immunol Immunother; 2019 Jul; 68(7):1171-1178. PubMed ID: 31172258
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial.
    Friedlander M; Meniawy T; Markman B; Mileshkin L; Harnett P; Millward M; Lundy J; Freimund A; Norris C; Mu S; Wu J; Paton V; Gao B
    Lancet Oncol; 2019 Sep; 20(9):1306-1315. PubMed ID: 31378459
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Phase 1b Study of Ivonescimab, a Programmed Cell Death Protein-1 and Vascular Endothelial Growth Factor Bispecific Antibody, as First- or Second-Line Therapy for Advanced or Metastatic Immunotherapy-Naive NSCLC.
    Wang L; Luo Y; Ren S; Zhang Z; Xiong A; Su C; Zhou J; Yu X; Hu Y; Zhang X; Dong X; Meng S; Wu F; Hou X; Dai Y; Song W; Li B; Wang ZM; Xia Y; Zhou C
    J Thorac Oncol; 2024 Mar; 19(3):465-475. PubMed ID: 37879536
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.